TY  - JOUR
AU  - Aldea, Mihaela
AU  - Lam, Laurent
AU  - Orillard, Emeline
AU  - Llacer Perez, Casilda
AU  - Saint-Ghislain, Mathilde
AU  - Gravis, Gwenaelle
AU  - Flechon, Aude
AU  - Roubaud, Guilhem
AU  - Barthelemy, Philippe
AU  - Ricci, Francesco
AU  - Priou, Frank
AU  - Neviere, Zoe
AU  - Beaufils, Mathilde
AU  - Laguerre, Brigitte
AU  - Hardy, Anne-Claire
AU  - Helissey, Carole
AU  - Ratta, Raffaele
AU  - Borchiellini, Delphine
AU  - Pobel, Cedric
AU  - Joly, Florence
AU  - Castro, Elena
AU  - Thiery-Vuillemin, Antoine
AU  - Baciarello, Giulia
AU  - Fizazi, Karim
PY  - 2021
DO  - 10.1016/j.ejca.2021.09.029
SN  - 0959-8049
UR  - https://hdl.handle.net/10668/26859
T2  - European journal of cancer
AB  - Background: Cabazitaxel was shown to improve overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) after abiraterone/enzalutamine and docetaxel failure, though benefit by the presence of DNA damage repair (DDR)...
LA  - en
PB  - Elsevier sci ltd
KW  - DNA damage repair
KW  - BRCA
KW  - Cabazitaxel
KW  - PARP inhibitors
KW  - mCRPC
KW  - Treatment outcomes
KW  - Gene-mutations
KW  - Phase-iii
TI  - Cabazitaxel activity in men with metastatic castration-resistant prostate cancer with and without DNA damage repair defects
TY  - research article
VL  - 159
ER  -